­
­
­
­

Inventi Rapid - Endocrinology
(Formerly Inventi Rapid/Impact: Diabetes)

Patent Watch

  • DIAGNOSTIC BIOMARKERS OF DIABETES

    Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.

  • PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS

    The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.

  • DIABETES THERAPEUTIC AGENT

    The problem of the present invention is to provide a compound useful for the prophylaxis or treatment of diseases related to the control of the differentiation of muscle cell or adipocyte differentiation, such as diabetes, obesity, dyslipidemia, and having a superior efficacy. The present invention provides an agent for the prophylaxis or treatment of diabetes, obesity or dyslipidemia, containing a compound represented by the formula (I) ##STR00001## wherein each symbol is as defined in the DESCRIPTION, or a salt thereof or a prodrug thereof.

  • COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION

    The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders.

  • BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS

    Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.

  • DIABETES MANAGEMENT APPLICATION FOR MOBILE PHONE

    A mobile device for managing diabetes care of a patent is disclosed. The device has a data entry interface configured to receive glucose measures for the patient and store the glucose measures in a patient log residing on the device. The device has a selection module that operates to selectively analyze the glucose measure in the patient log and select a given structural collection procedure from a plurality of standardized collection procedures.

  • METHOD OF TREATING DIABETES-RELATED IMPAIRED WOUND HEALING

    The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-.alpha. inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-.alpha. inhibitor to a patient in need thereof to promote wound healing.

  • INSULIN GLARGINE VERSUS METFORMIN FOR THE FIRST-LINE TREATMENT OF EARLY TYPE-2 DIABETES

    The invention relates to a method for treating type 2 diabetes patients, wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective, wherein the type 2 diabetes is early type 2 diabetes, more particularly, wherein the insulin glargine is used as first-line drug.

  • HANDHELD DIABETES MANAGER WITH AUTOMATED DISCONNECT FEATURE

    A computer-implemented method is provided for a handheld diabetes-management device to establish a data connection with a Continua manager. The method includes: receiving a request to establish a new data connection with a computing device, where the computing device is physically separated from the diabetes-management device and operates as a manager in accordance with IEEE standard 11073; determining whether the diabetes-management device has an existing data connection with a medical device that is physically separated from the diabetes-management device; terminating the existing data connection with the medical device in response to the determination that the diabetes-management device has an existing connection with the medical device; and establishing a new data connection with the computing device in accordance with IEEE standard 11073.

  • OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES

    The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, ##STR00001## wherein A, B, C, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.

  • FREEZE DRIED EXTRACT OF PARKIA, PREFERABLY OF PARKIA SPECIOSA BEANS FOR TREATMENT OF DISEASES SUCH AS DIABETES MELLITUS TYPE 2

    The invention relates to a process for the preparation of a freeze-dried fruit of Parkia, preferably Parkia speciosa comprising the steps of a) freezing a fruit, preferably beans from Parkia to -20.degree. C. or below to obtain a frozen fruit and b) subsequently freeze-drying the frozen fruit by reducing the pressure surrounding the said frozen fruit to allow water and volatiles to sublimate and/or evaporate from the frozen fruit to obtain the freeze-dried fruit of Parkia, wherein the temperature of the fruit during freeze-drying is at most 0.degree. C., wherein the temperature of the fruit from the beginning of step a) until the end of step b) does not exceed 30.degree. C. The invention also relates to the products obtained with the process, including their use as a medicament in the treatment, co-treatment and/or prevention of diabetes mellitus and/or for weight regulation.

  • METHOD FOR TREATING AND PREVENTING TYPE 2 DIABETES

    Methods and compositions for treating or preventing type 2 diabetes by inhibiting expression or activity of monoacylglycerol O-acyltransferase 1 (MOGAT1) are disclosed. Also disclosed are methods to identify such compositions.

  • COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES

    A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.

  • Therapeutic or Preventive Agent for Diabetes

    A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly).sub.5, Pro-Hyp, Hyp-Gly, Pro-Gly, Pro-Pro and Ala-Hyp or a chemically-modified substance thereof or a pharmaceutically acceptable salt thereof have DPPTV inhibitory activity and/or GLP-1 secretion accelerating activity, and hence are effective as a therapeutic or preventive agent or the like for diabetes.

  • SYSTEMS AND METHODS FOR TREATING OBESITY AND TYPE 2 DIABETES

    The present invention provides systems and methods for treating wounds in patients who lack the innate ability to regulate glucose (e.g., diabetic patients). In one aspect of the invention, a method includes positioning an internal bypass device within the duodenum to inhibit contact between chyme passing therethrough and an internal wall of the duodenum and maintaining the internal bypass device within the duodenum for a sufficient period of time to decrease insulin resistance and reduce a blood glucose level in the patient. The internal bypass device increases peripheral blood flow and elevates an immune system response to accelerate healing of the wound.

  • HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS

    Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.

  • METHOD FOR TREATING TYPE 1 DIABETES

    The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

  • MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES

    Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex. In some embodiments, the proteomic profile may also include information on the expression of adiponectin, sex hormone binding globulin (SHBG), C-reactive protein (CRP), a ratio of human chorionic gonadotropin (hCG) to placental lactogen, or a combination thereof.

  • AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

    The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. ##STR00001##

  • OPTIMIZATION-BASED REGIMEN METHOD AND SYSTEM FOR PERSONALIZED DIABETES AND DIET MANAGEMENT

    Methods and systems for determining computer optimization-based regimens and/or plans and/or programs for diet and health management are presented. A regimen and/or plan and/or program is generated by a computer (i) obtaining for an individual, a nutritional-based metabolic response as a function of time associated with a set of nutritional components, (ii) obtaining for the individual, an exercise-based metabolic response as a function of time associated a set of exercises available for performance by the individual, (iii) optimizing using computer optimization applied to the nutrition-based metabolic responses and the exercise-based metabolic responses, to determine a regimen defining for a time interval a sequence of one or more nutritional components to be ingested by the individual, and a sequence of one or more exercises to be performed by the individual, whereby one or more individual-based parameters are maintained in a predetermined range.

  • THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES

    The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject.

  • NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY

    Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of diabetes. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl).

  • RBP4 IN INSULIN SENSITIVITY/RESISTANCE, DIABETES, AND OBESITY

    Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity.

  • URSOLIC ACID SALTS FOR TREATING DIABETES AND OBESITY

    The present invention relates to compounds having the following structure: ##STR00001## wherein R is H or OH and X.sup.+ is protonated metformin, protonated arginine, protonated lysine and protonated meglumine. The invention also relates to intermediates used in the preparation of such compounds, processes for the preparation of such compounds and intermediates, pharmaceutical compositions comprising such compounds and the methods of treatment using such compounds as antidiabetic, antiobesity, and antisarcopenia agents.

  • METHOD AND SYSTEM TO INDICATE HYPERGLYCEMIA OR HYPOGLYCEMIA FOR PEOPLE WITH DIABETES

    Various methods and systems to manage diabetes of a subject using data relating to patterns to provide insight into how a patient's daily activities impact glycemic control of the subject. These patterns help to identify very specific areas of glycemic excursions, enable patients and HCPs to more easily identify patterns of hypoglycemia and hyperglycemia in order to take steps to improve glycemic control of the person with diabetes.

  • CICLETANINE IN COMBINATION WITH ORAL ANTIDIABETIC AND/OR BLOOD LIPID-LOWERING AGENTS AS A COMBINATION THERAPY FOR DIABETES AND METABOLIC SYNDROME

    Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microalbuminuria, nephropathies, retinopathies and other complications) in patients with diabetes or metabolic syndrome.